DOI: https://doi.org/10.24959/cphj.20.1524

Analysis of the range of antifungal drugs for systemic use and evidence-based clinical efficacy and safety of fluconazole

O. V. Tkachоva, T. I. Sheptak

Abstract


Today, according to the WHO, every fifth inhabitant of the Earth is infected with fungi, and every tenth has pronounced clinical manifestations of fungal diseases. The incidence of mycotic foot infections among the population both in Ukraine and in various European countries varies from 20 to 70 %.

Aim. To analyze the assortment of antifungal drugs for systemic use at the pharmaceutical market of Ukraine within 2016-2018 and the evidence base for efficacy and safety of the antifungal drug – fluconazole.

Materials and methods. The analysis of the assortment of antifungal drugs was performed within 2016-2018 according to the “Pharmstandard” information and search system “Morion” of company. The analysis of clinical efficacy and safety of fluconazole was carried out according to the evidence-based medicine databases, such as Cochrane Library, Trip Database, PubMed, Nice.

Results. Antifungal drugs for systemic use were presented at the pharmaceutical market within 2016-2018 in a sufficient assortment (103-111 TN drugs) based on 7 INN. However, most INN drugs were presented by 1-4 TN and had a narrow price range per package. Only fluconazole preparations had a significant amount of TH at the market (79-89 TN drugs) with a wide range of prices per package (from 8.63 to 1407.29 UAH). In 10 systematic reviews analyzed the results of clinical efficacy and safety of fluconazole for the prevention and treatment of fungal infections in children and adults were presented. Fluconazole has the proven pronounced clinical efficacy and is recommended by the American and European Communities of Infectious Diseases as a first-line therapy for candida infections.

Conclusions. The analysis of systematic reviews and meta-analyses prove the safety and efficacy of fluconazole when used in children and adults for the prevention and treatment of fungal infections.

Keywords


fungal infections; antifungal drugs; assortment of medicines; pharmaceutical market; clinical efficacy and safety of fluconazole

References


Korolenko, V. V. (2010). Suchasnyi stan problemy mikoziv ta zastosuvannia serta-konazolu v yikh likuvanni. Ukrainskyi zhurnal dermato-lohii, venerolohii, kosmetolohii, 3(38),109–116.

Kuts, L. V., Hortynska, O. M. (2019). Mikozy: navchalnyi posibnyk. Sumy: Sumskyi derzhavnyi universytet, 83.

Koliadenko, V. H., Korolenko, V. V. (2003). Suchasni pohliady na klasyfikatsiiu mikroorhanizmiv – zbudnykiv shkirnykh ta venerychnykh khvorob. Ukrainskyi zhurnal dermatolohii, venerolohii, kosmetolohii, 3, 7–11.

Koroleva, Zh. V. (2013). Etiologiia, klinika i optimizatciia terapii pri mikoze stop. Ukrainskyi zhurnal dermatolohii, venerolohii, kosmetolohii, 2(49), 171–175.

Systema doslіdzhennia rinku lіkarskikh zasobіv «Pharmexplorer» kompanії «Morіon». (n.d.). Available at: https://www.pharmstandart.com.ua

Podobed, V. M. (2011). Sovremennyi vzgliad na problemu kandidoza i vozmozhno-sti flukonazola. Meditcinskie novosti, 8, 57–59.

Kontoyiannis, D. P., Bodey, G. P., Mantzoros, C. S. (2001). Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis: Mycoses, 44(5), 125–135. https://doi.org/10.1046/j.1439-0507.2001.00649.x

Shorr, A. F., Chung, K., Jackson, W. L., Waterman, P. E., & Kollef, M. H. (2005). Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis*. Critical Care Medicine, 33(9), 1928–1935. https://doi.org/10.1097/01.ccm.0000178352.14703.49

Chen, H., Suda, K. J., Turpin, R. S., Pai, M. P., Bearden, D. T., & Garey, K. W. (2007). High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis. Current Medical Research and Opinion, 23(5), 1057–1065. https://doi.org/10.1185/030079907x182130

Lalla, R. V., Latortue, M. C., Hong, C. H., Ariyawardana, A., D’Amato-Palumbo, S., … Brennan, M. T. (2010). A systematic review of oral fungal infections in patients receiving cancer therapy. Supportive Care in Cancer, 18(8), 985–992. https://doi.org/10.1007/s00520-010-0892-z

Smego, R. A., & Ahmad, H. (2011). The Role of Fluconazole in the Treatment of Candida Endocarditis. Medicine, 90(4), 237–249. https://doi.org/10.1097/md.0b013e3182259d38

Chicella, M. F., Woodruff, E. D., Desai, M. M. (2012). A review of Candida prophylaxis in the neonatal intensive care population. Journal of Pediatric Pharmacology and Therapeutics, 16(4), 237–245.

Blyth, C. C., Barzi, F., Hale, K., & Isaacs, D. (2012). Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin. Journal of Paediatrics and Child Health, 48(9), 846–851. https://doi.org/10.1111/j.1440-1754.2012.02543.x

Gøtzsche, P. C., & Johansen, H. K. (2014). Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database of Systematic Reviews, 4(9). https://doi.org/10.1002/14651858.cd002033.pub2

Rios, J. F. da S., Camargos, P. A. M., Corrêa, L. P., & Romanelli, R. M. de C. (2017). Fluconazole prophylaxis in preterm infants: a systematic review. The Brazilian Journal of Infectious Diseases, 21(3), 333–338. https://doi.org/10.1016/j.bjid.2017.01.008

Qin, F., Wang, Q., Zhang, C., Fang, C., Zhang, L., Chen, H., … Cheng, F. (2018). Efficacy of antifungal drugs in the treatment of vulvovaginal candidiasis: a Bayesian network meta-analysis. Infection and Drug Resistance, 11, 1893–1901. https://doi.org/10.2147/idr.s175588


GOST Style Citations


1. Короленко, В. В. Сучасний стан проблеми мікозів та застосування сертаконазолу в їх лікуванні / В. В. Короленко // Укр. журн. дерматол., венерол., косметол. – 2010. – № 3 (38). – С. 109–116.

 

2. Куц, Л. В. Мікози : навч. посібник / Л. В. Куц, О. М. Гортинська. – Суми : Сумський державний університет, 2019. – 83 с.

 

3. Коляденко, В. Г. Сучасні погляди на класифікацію мікроорганізмів – збудників шкірних та венеричних хвороб / В. Г. Коляденко, В. В. Короленко // Укр. журн. дерматол., венерол., косметол. – 2003. – № 3. – С. 7–11.

 

4. Королева, Ж. В. Этиология, клиника и оптимизация терапии при микозе стоп / Ж. В. Королева // Укр. журн. дерматол., венерол., косметол. – 2013. – № 2 (49). – С. 171–175.

 

5.    Система дослідження ринку лікарських засобів «Pharmexplorer» компанії «Моріон». [Електронний ресурс]. – Режим доступу : https://www.pharmstandart.com.ua

 

6.    Подобед, В. М. Современный взгляд на проблему кандидоза и возможности флуконазола / В. М. Подобед // Медицинские новости. – 2011. – № 8. – С. 57–59.

 

7.    Kontoyiannis, D. P. Fluconazole vs. amphotericin B for the management of candidaemia in adults : a meta-analysis / D. P. Kontoyiannis, G. P. Bodey, C. S. Mantzoros // Mycoses. – 2001. – Vol. 44 (5). – P. 125–135. https://doi.org/10.1046/j.1439-0507.2001.00649.x 

 

8.    Fluconazole prophylaxis in critically ill surgical patients: a meta-analysis / A. F. Shorr, K. Chung, W. L. Jackson et al. // Critical Care Medicine. – 2005. – Vol. 33 (9). – P. 1928–1935. https://doi.org/10.1097/01.ccm.0000178352.14703.49 

 

9.    High-versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis / H. Chen, K. J. Suda, R. S. Turpin et al. // Curr. Med. Res. Opin. – 2007. – Vol. 23 (5). – P. 1057–1065. https://doi.org/10.1185/030079907x182130 

 

10.  A systematic review of oral fungal infections in patients receiving cancer therapy / R. V. Lalla, M. C. Latortue, C. H. Hong et al. // Support Care Cancer. – 2010. – Vol. 18 (8). – P. 985–992. https://doi.org/10.1007/s00520-010-0892-z 

 

11.  Smego, R. A. The role of fluconazole in the treatment of Candida endocarditis: a meta-analysis / R. A. Smego, H. Ahmad // Medicine. – 2011. – Vol. 90 (4). – P. 237–249. https://doi.org/10.1097/md.0b013e3182259d38 

 

12.  Chicella, M. F. A review of Candida prophylaxis in the neonatal intensive care population / M. F. Chicella, E. D. Woodruff, M. M. Desai // J. of Pediatric Pharmacol. and Therapeutics. – 2012. – Vol. 16 (4). – P. 237–245.

 

13.  Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin / C. C. Blyth, F. Barzi, K. Hale, D. Isaacs // J. of Paediatrics and Child Health. – 2012. – Vol. 48 (9). – P. 846–851. https://doi.org/10.1111/j.1440-1754.2012.02543.x 

 

14.  Gøtzsche, P. C. Nystatin prophylaxis and treatment in severely immunodepressed patients / P. C. Gøtzsche, H. K. Johansen // Cochrane Database Syst. Rev. – 2014. – № 4 (9). https://doi.org/10.1002/14651858.cd002033.pub2 

 

15.  Fluconazole prophylaxis in preterm infants: a systematic review / J. F. D. S. Rios, P. A. M. Camargos, L. P. Corrêa, R.M.C.Romanelli // Braz. J. Infect. Dis. – 2017. – Vol. 21 (3) – P. 333–338. https://doi.org/10.1016/j.bjid.2017.01.008 

 

16. Antifungal efficacy in the treatment of vulvovaginal candidiasis: Bayesian network meta-analysis / F. Qin, Q. Wang, S. Zhang et al. // Infect. Drug Resist. – 2018. – Vol. 11. – P. 1893–1901. https://doi.org/10.2147/idr.s175588




Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Abbreviated key title: Clin. pharm.

ISSN 2518-1572 (Online), ISSN 1562-725X (Print)